NDAINTRAVENOUSSOLUTION
Approved
Jan 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
DAPTOMYCIN IN 0.9% SODIUM CHLORIDE (daptomycin in sodium chloride) by Baxter is 12. Approved for pneumonia, left-sided infective endocarditis due to s, complicated skin and 16 more indications. First approved in 2022.
Drug data last refreshed 20h ago
Mechanism of Action
12.1 Mechanism of Action Daptomycin is an antibacterial drug [see ] . 12.2 Pharmacodynamics Based on animal models of infection, the antimicrobial activity of daptomycin appears to correlate with the AUC/MIC (area under the concentration-time curve/minimum inhibitory concentration) ratio for…
Worked on DAPTOMYCIN IN 0.9% SODIUM CHLORIDE at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.